Astrazeneca Pharma India hits 2-year high on regulatory import approval

Astrazeneca Pharma India

25/07/2023 06:01

** Shares of Astrazeneca Pharma India  ASTR.NS  rise as much
as 3.5% to 3,899.95 rupees, their highest since June 14, 2021
    ** Stock logs its highest intraday pct climb since May 31
    ** Co on Monday said it received permission from Drugs
Controller General of India to import pharmaceutical
formulations of Dapagliflozin Tablets 10 mg
    ** Says the drug is for heart disease treatment in adults 
    ** More than 8,000 shares change hands, 0.5X the 30-day
moving average
    ** Stock up 14.3% YTD, as of last close    
    

 (Reporting by Varun Vyas in Bengaluru)
 ((varunvyas.hebbalalu@thomsonreuters.com))